The Filing Desk

Insmed vs Ultragenyx Pharmaceutical

Insmed INSM · Ultragenyx Pharmaceutical RARE · Pharmaceuticals

Ultragenyx Pharmaceutical reported revenue of $673 million in fiscal 2025, about the same as Insmed's $606 million in fiscal 2025. Insmed's revenue grew 66.7% in its latest year, and Ultragenyx Pharmaceutical's grew 20.2%. Insmed had an operating margin of -205.6%, against -79.5% at Ultragenyx Pharmaceutical. Free cash flow was −$968 million at Insmed and −$472 million at Ultragenyx Pharmaceutical.

Side by side

InsmedUltragenyx Pharmaceutical
Latest fiscal yearFY2025, Dec 31, 2025FY2025, Dec 31, 2025
Revenue$606M$673M
Revenue growth66.7%20.2%
Revenue growth a year, last 5 years29.8%20.0%
Gross margin79.7%—
Operating margin−205.6%−79.5%
Net margin−210.5%−85.4%
Free cash flow−$968M−$472M
Free cash flow margin−159.6%−70.1%
Return on capital——
Net debt to EBITDA——
Dividends and buybacks$0M$0M
Change in diluted share count21.3%8.9%
Last close$144.46$17.22
P/E at the last close——
Insider trades, last 12 monthssold $133.7 millionsold $3.7 million
Piotroski F-score5 of 9—
Amounts in each company's own currency, US$ unless marked (a foreign company may report in another), each company's latest fiscal year from its 10-K, or 20-F or 40-F for a foreign company. Growth rates compare with the year before; the five-year rate is the average a year. Free cash flow is cash from operations minus capital spending; return on capital is after-tax operating income over the money invested in the business; P/E is the last close over the latest earnings per share. Banks are measured differently (return on equity, efficiency ratio), so some rows apply to one company only.

Ten years

Revenue
US$ billions, fiscal years
InsmedUltragenyx Pharmaceutical
Operating margin
Percent of revenue
InsmedUltragenyx Pharmaceutical
Free cash flow
US$ billions. Cash from operations minus capital expenditure.
InsmedUltragenyx Pharmaceutical

Start a new comparison

Source: the companies' Form 10-K filings, from SEC EDGAR, and the last close. For information only, not investment advice: the figures describe results, not which company is the better investment. The Filing Desk is not affiliated with either company. Full figures on the Insmed and Ultragenyx Pharmaceutical pages.